The market has climbed 1.5% in the last 7 days and is up 26% over the last 12 months, with earnings forecast to grow by 17% annually. While the term 'penny stock' might seem outdated, these investments still offer potential value by focusing on smaller or newer companies with strong financials. In this article, we explore three penny stocks that demonstrate financial strength and could present opportunities for investors seeking hidden value in quality companies.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Rewards & Risks
ZJK Industrial (ZJK)	$2.76	$187.82M	✅ 3 ⚠️ 2 View Analysis >
Waterdrop (WDH)	$1.55	$571.29M	✅ 4 ⚠️ 0 View Analysis >
LexinFintech Holdings (LX)	$2.05	$349.99M	✅ 3 ⚠️ 2 View Analysis >
Information Services Group (III)	$3.11	$198.05M	✅ 3 ⚠️ 0 View Analysis >
Golden Growers Cooperative (GGRO.U)	$5.00	$77.45M	✅ 2 ⚠️ 5 View Analysis >
Niagen Bioscience (NAGE)	$3.85	$317.65M	✅ 3 ⚠️ 1 View Analysis >
Cricut (CRCT)	$4.26	$915.16M	✅ 2 ⚠️ 2 View Analysis >
Village Farms International (VFF)	$2.67	$301.72M	✅ 5 ⚠️ 1 View Analysis >
BAB (BABB)	$0.9416	$6.92M	✅ 2 ⚠️ 3 View Analysis >
Marine Petroleum Trust (MARP.S)	$4.9663	$10M	✅ 2 ⚠️ 3 View Analysis >

Below we spotlight a couple of our favorites from our exclusive screener.

Oramed Pharmaceuticals (ORMP)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Oramed Pharmaceuticals Inc. focuses on the research and development of pharmaceutical solutions using a technology platform for oral delivery of therapeutic proteins, with a market cap of approximately $186.86 million.

Operations: Oramed Pharmaceuticals generates revenue of $2 million from research and development activities related to its proprietary products and technologies.

Market Cap: $186.86M

Oramed Pharmaceuticals has recently transitioned to profitability, reporting a net income of US$64.05 million for the year ended December 31, 2025. Despite generating limited revenue of US$2 million, the company benefits from a strong balance sheet with no debt and substantial short-term assets of US$133.3 million exceeding both short and long-term liabilities. The experienced management team and board contribute to its strategic stability, while its low price-to-earnings ratio (2.8x) suggests potential value compared to the broader market average (19x). Recent share buybacks indicate confidence in future prospects without significant shareholder dilution.

MacroGenics (MGNX)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing antibody-based cancer therapeutics in the United States, with a market cap of $187.50 million.

Operations: The company's revenue is derived from developing and commercializing monoclonal antibody-based therapeutics, totaling $149.5 million.

Market Cap: $187.5M

MacroGenics, Inc., a clinical-stage biopharmaceutical company, is navigating financial challenges with a net loss of US$74.62 million in 2025 despite generating US$149.5 million in revenue. The company remains unprofitable and is not expected to achieve profitability in the next three years. However, it benefits from a robust cash position with short-term assets of US$219.9 million surpassing liabilities and no debt burden, providing a cash runway exceeding one year at current free cash flow levels. Recent developments include the FDA lifting a partial clinical hold on its Phase 2 LINNET study after addressing safety concerns through revised protocols.

Treace Medical Concepts (TMCI)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Treace Medical Concepts, Inc. is a medical technology company that designs, manufactures, and markets medical devices in the United States with a market cap of approximately $125.85 million.

Operations: Treace Medical Concepts, Inc. has not reported any specific revenue segments.

Market Cap: $125.85M

Treace Medical Concepts, Inc. faces financial hurdles with a net loss of US$17.96 million in Q1 2026 and declining sales from the previous year. Despite these challenges, the company maintains a satisfactory net debt to equity ratio of 7.4% and has experienced management and board teams with average tenures of over four years. Treace's short-term assets exceed both its long-term and short-term liabilities, indicating solid liquidity management. The recent introduction of innovative products like the SuperBite Compression Screw System could expand its market by an estimated US$300 million, potentially enhancing future revenue streams despite current unprofitability challenges.

Turning Ideas Into Actions

• Access the full spectrum of 348 US Penny Stocks by clicking on this link.
• Contemplating Other Strategies? Uncover 23 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.